These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39028654)

  • 41. Clinician Willingness to Prescribe Medications for Opioid Use Disorder to Adolescents in Indiana.
    Aalsma MC; Bell LA; Schwartz K; Ouyang F; Kolak M; Monahan PO; Mermelstein SP; Carson I; Hulvershorn LA; Adams ZW
    JAMA Netw Open; 2024 Sep; 7(9):e2435416. PubMed ID: 39320891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
    Johnson K; Hills H; Ma J; Brown CH; McGovern M
    Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
    [No Abstract]   [Full Text] [Related]  

  • 43. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
    Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
    [No Abstract]   [Full Text] [Related]  

  • 44. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.
    Jordan AE; Bachhuber MA; Tuazon E; Jimenez C; Lincourt P; Hussain S; Rubinfeld J; Cunningham CO
    Drug Alcohol Depend; 2024 May; 258():111283. PubMed ID: 38581920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Racial and Ethnic Disparities in Take-Home Methadone Use for Medicare Beneficiaries With Opioid Use Disorder.
    Choi S; Zhang Y; Unruh MA; McGinty EE; Jung HY
    JAMA Netw Open; 2024 Aug; 7(8):e2431620. PubMed ID: 39212993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
    Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
    BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
    Morgan JR; Quinn EK; Chaisson CE; Ciemins E; Stempniewicz N; White LF; Linas BP; Walley AY; LaRochelle MR
    Med Care; 2022 Mar; 60(3):256-263. PubMed ID: 35026792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD).
    Herrera MC; Johnson J; Lim S; Morales KH; Wilson JD; Hadland SE; Metzger D; Wood S; Dowshen N
    Drug Alcohol Depend; 2024 Apr; 257():111132. PubMed ID: 38387256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY; Schiff DM; Jones HE; Martin CE; Kelly JC; Bierut LJ; Carter EB; Grucza RA
    J Gen Intern Med; 2023 Dec; 38(16):3499-3508. PubMed ID: 37436568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.
    Pro G; Montgomery BEE; Zaller N
    Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):50. PubMed ID: 34147098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A trial of implementation facilitation to increase timely admission to methadone treatment.
    Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
    J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Availability of Medications for Opioid Use Disorder in Community Mental Health Facilities.
    Cantor J; Griffin BA; Levitan B; Mendon-Plasek SJ; Stein BD; Hunter SB; Ober AJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417545. PubMed ID: 38888921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cost of opioid use disorder-related conditions in Medicare.
    Mark TL; Parish WJ; Weber EM; Steinberg DG; Henretty K
    Drug Alcohol Depend; 2023 Mar; 244():109778. PubMed ID: 36701935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status.
    Pro G; Tompkins DA; Azari S; Zaller N
    Drug Alcohol Depend; 2021 Nov; 228():109092. PubMed ID: 34571287
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study.
    Knight D; Nkya IH; West NS; Yang C; Kidorf M; Latkin C; Saleem HT
    Addict Sci Clin Pract; 2023 Mar; 18(1):19. PubMed ID: 36973794
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Access to treatment before and after Medicare coverage of opioid treatment programs.
    Liu R; Beetham T; Newton H; Busch SH
    Health Aff Sch; 2024 Jun; 2(6):qxae076. PubMed ID: 38938273
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.